We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
10/6/2022 07:18 | Update looks good to me. | capitalist | |
29/3/2022 10:22 | Includes £3m contingent earn out deemed employment cost | phillis | |
29/3/2022 07:08 | Super results yet again - above expectations. This stock deserves a premium rating. | ihatemms | |
17/2/2022 17:27 | ...from last year... Company overview: Founded in 1997, Ergomed plc is a specialist services provider for the pharmaceutical industries, covering all phases of clinical development, post-approval pharmacovigilance and medical information. The company operates in more than 100 countries through its Pharmacovigilance and Clinical research Outsourcing service lines. The company has made several acquisitions over the past 5 years. Last three years’ performance is categorized by steady growth in Revenue, gross Profit and adjusted EBITDA and order book growth in 2020 of 55.5%. Acquisition in 2020 was in the USA with ambition to increase market presence for both business lines. Revenue in USA is currently accounting for around 54%, compared to UK’s 14% and EU area 27%. Latest update from the company shows strong trade with 38% growth in revenue in the first half of the year bringing the interim figure to £56m. CRO division generated a staggering 90.7%. Healthy balance sheet and prospects for growth are firmly supported by increase in cash balance to £24.6m and growth in order book at 18% since 01/01/2021....from WealthOracleAM | km18 | |
09/2/2022 10:58 | A boring acquisition - £1.8m "adjusted" EBITDA for £25.6m Can that be said to be a 7.0% ROCE? I'm not an accountant but that does not seem very earnings enhancing so hopefully the 'fringe' benefits ... more customers, offices etc will be worthwhile Also the webcast was dry and without enthusiasm. AIMHO | piedro | |
03/2/2022 10:49 | Might reach £16 one day but not this year | phillis | |
03/2/2022 05:21 | Paul Jourdan of Amati Global talks positively about Ergomed here (starts 35:55) www.youtube.com/watc | brummy_git | |
25/1/2022 10:52 | Great update from a great company. | blueflame | |
25/1/2022 09:20 | Hi Guys, I appreciate we're all a bit share shocked but this was an excellent trading update: >> Adjusted EBITDA ahead of mkt expectations (1) >> Revenue growth 37.3% (44.3% at constant currency) >> US very strong growth 59.5% (71% at constant currency) >> Throwing off cash. And the Outlook is positive - order book is up 24% and in value is twice 2021 revenue. So, conversion should ensure strong growth continues. Regards Maddox (1) I wish they would state a figure for 'market expectations' - it's public domain so why not? | maddox | |
25/1/2022 07:46 | Good trading update - business as usual "Adjusted EBITDA for the year ended 31 December 2021 is expected to be ahead of current market expectations, reflecting the excellent operational execution and profit focus delivered across the business." | piedro | |
21/1/2022 11:27 | On the contrary Way undervalued , the trading update ,next week will confirm my that. | bramble13 | |
19/1/2022 13:21 | good business was way overvalued | phillis | |
19/1/2022 10:02 | ERGO is an Ex-holding that did exceptionally well for me. However, in this market, I do question the PE valuation ascribed to the businesses by the market. I think that ERGO is a fine business but will wait until the next trading update before I reconsider taking a fresh position. I expect the next trading update to be in eh last week of this month. | whittler100 | |
18/1/2022 10:30 | Plenty of action this morning. | achenaton | |
18/1/2022 10:20 | Good for you Phillis,make hay while the sun shines.The trading update is due towards the end of the month and then we will see some real action. | bramble13 | |
05/1/2022 15:17 | This is proving to be a nice trading stock Sold at £15.50 yesterday and bought back today at £14.14 | phillis | |
13/12/2021 11:44 | This share is up and down like the whoares draws on boat race night | walkernbudgie | |
26/11/2021 11:18 | It is going up but it is battling a falling market.I think we can see some fairly good gains , despite the market. | bramble13 | |
26/11/2021 09:16 | I would have thought this would be up today and not down as this is surely a reminder that Ergomed’s businesses are likely to continue to boom. | blueflame | |
25/11/2021 18:53 | Not that much volatility around You must be piling in at these levels no? | phillis |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions